House Republicans say the federal 340B drug discount program has major problems and a legislative solution is one the way.
Pharmaceutical companies and congressional Republicans say the program has grown beyond its original intent of helping indigent patients with their drug costs. Congress didn’t clearly identify the intent of the program when it was created in 1992, Rep. Greg Walden (R-Ore.) said Jan. 9 during a call with reporters.
Walden’s press call was in advance of the Jan. 10 release of a report by the House Energy and Commerce Committee, which provides recommendations for how the program could be improved. Walden is the chairman of that committee.
“Everyone has a different idea of what Congress meant with the language that created the program,” Walden said. “It’s time for Congress to do its job and step up and give definition, transparency, and accountability to the 340B program.”
Walden said his committee will be advancing legislation in the first few months of 2018 and it’s one of his top priorities. He said the legislation should clarify the intent of the program. He also said it should clearly define how covered entities should use the savings they receive from the program and establish uniform reporting requirements.
Meanwhile, the leading Democrat on the committee offered support for the 340B program.
The committee’s investigation “has shown the 340B program to be an essential source of cost savings for covered entities such as safety net hospitals, children’s hospitals, community health centers, and Ryan White HIV/AIDS Program Grantees,” Rep. Frank Pallone Jr. (D-N.J.) said in Jan. 10 statement. He noted that the 340B program has strong bipartisan support in Congress.
Read my full article here.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)